Share Twitter LinkedIn Facebook Email Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior Imedex Great Debates 2018.
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope ASCO Annual Meeting 2 Mins Read